Promomed

PROMOMED Public joint-stock company is a leading innovative biopharmaceutical com-pany with attractive growth potential in promising segments of the pharmaceutical market. The Company has unique R&D Hub and manufacturing plant named BIOKHIMIK. This al-lows PROMOMED to develop innovative medicines, benefit from a full production cycle based on “From Idea, to Molecule, to Patient” concept, be fast in responding to unmet needs in healthcare, implement up-to-date technology solutions. PROMOMED is ranked #1 in Obesity treatment segment being an expert in metabolic health therapy. The Company is #1 in Russia in terms of the number of clinical trials and medical studies in 2022-2023.The Company is among TOP-3 in the relevant market segments in Onco, Antibiotics, HIV, Hepatitis. PROMOMED has a diversified portfolio of more than 330 medicines and is represented in all TOP-10 of the biggest and fastest growing therapeutic areas in the local market, such as On-co, Diabetes, Obesity, Neuro, Rheuma, Pain, etc. More than 80% of PROMOMED products are listed as live-saving products in the local Essential Drug List (EDL). The main drivers in the Com-pany's products range are branded pharmaceutical blockbusters, biotech products, innovative small molecules, as well as OTC brands. The state-of-the-art R&D Hub underpins advanced healthcare solutions and creates a solid background for business development. In addition to laboratories and centers for the develop-ment of Biotech and Small molecules, R&D Hub develops active drug substances, ensures regis-tration service, technology transfers and production scaling, leads market authorization and sup-ports the development of advanced Quality controls methods. The Company’s deep expertise in the field of innovative chemical technologies and Bio-tech, combined with modern manufacturing plant, allow PROMOMED to occupy leading positions in various professional ratings and ensure her active and important contribution to local Healthcare system